Paul Breillat: Targeting Inflammatory Cell Death Pathways in VEXAS Syndrome
Paul Breillat, Assistant Clinical Fellow in Internal Medicine and Clinical Immunology at Cochin Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Excited to share our new publication in Blood on VEXAS syndrome!
In this study, we uncover a pathogenic axis in VEXAS linking UBA1 loss of function and defective ubiquitination to:
- RIPK1-mediated inflammatory cell death
- Impaired antimicrobial signaling
- Defective resolution of inflammation
These findings provide evidence that targeting inflammatory cell death pathways represents a promising therapeutic strategy in VEXAS syndrome.
This work would not have been possible without our extraordinary collaborators David Beck, Samuel Magaziner, Stéphane Camus.
Warm thanks to the Foundation for Medical Research and Fonds IMMUNOV for their invaluable support.
Thanks also to the team at Paris Cardiovascular Research Center – PARCC and to INSERM for providing such a stimulating research environment.
Finally, special thanks to Benjamin Terrier for his mentorship and guidance throughout this project.”
Title: Inflammatory cell death and monocyte dysfunction in VEXAS syndrome
Authors: Paul Breillat, Samuel J Magaziner, Stéphane M. Camus, Léa Dionet, Benjamin De Valence De Minardiere, Pierre Sohier, Amine Majdi, Quentin Delcros, Federica Pallotti, Nadia Rivet, Kevin Chevalier, Margot Poux, Sr., Athena Lam, Pierre-Louis Tharaux, Olivia Lenoir, Abdelrahim Zoued, Olivier Kosmider, David B. Beck, Benjamin Terrier
Read the Full Article on Blood.

Stay updated on all scientific advances with Hemostasis Today.
-
Jun 9, 2026, 17:55Can We Prevent Postpartum Blood Clots without Putting Most Women on Heparin? – RPTH Journal
-
Jun 9, 2026, 17:54Lucky Oseghale Oloboh: Health Is Power, Health Is Personal, and Health Is Our First Responsibility in Life’s Journey on Mother Earth
-
Jun 9, 2026, 17:53Ajay Samkaria: How ABO Subgroups Directly Impact Transfusion Safety
-
Jun 9, 2026, 17:51Alejandro González Veliz: Most Reported Aspirin Allergies Are Not True Hypersensitivity
-
Jun 9, 2026, 17:50Mary Cushman: It’s Time to Apply to Be on an ISTH SSC
-
Jun 9, 2026, 15:56Wolfgang Miesbach: A New Genetic Perspective on the Worldwide Burden of von Willebrand Disease
-
Jun 9, 2026, 15:34Shanon Marie Corsino: Nationwide Insights into Cancer-Associated Thrombosis in Filipino Patients
-
Jun 9, 2026, 15:20Murtuza Ali: Types of Blood Transfusions – A Quick Clinical Guide
-
Jun 9, 2026, 15:18Mital Jhaveri: TRACK Trial Findings Highlight the Unique Challenges of Advanced CKD